Table 1.
Baseline clinical characteristics of the total patient population and divided according to the presence (E/SRIVR ≥ 236) or not (E/SRIVR < 236) of significant left ventricular diastolic dysfunction.
| All patients (n = 77) | E/SRIVR < 236 (n = 40) | E/SRIVR ≥ 236 (n = 37) | |
|---|---|---|---|
| Age (yrs.) | 67.2 ± 7.8 | 66.9 ± 8.3 | 67.7 ± 7.4 |
| Male gender | 57 (74.0%) | 28 (70.0%) | 29 (78.4%) |
| Hemodialysis | 46 (59.7%) | 19 (47.5%) | 27 (73.0%)* |
| Dialysis vintage (months) | 16 [9,34] | 12 [8,26] | 21 [10,52] |
| NYHA class | |||
| I | 52 (68.5%) | 30 (75.0%) | 22 (59.5%) |
| II/III | 25 (31.5%) | 10 (25.0%) | 15 (40.5%) |
| Hypertension | 67 (87.0%) | 31 (77.5%) | 36 (97.3%)* |
| BSA | 1.93 ± 0.21 | 1.93 ± 0.20 | 1.92 ± 0.21 |
| Diabetes mellitus | 24 (31.2%) | 8 (20.0%) | 16 (43.3%)* |
| Myocardial infarction | 21 (27.3%) | 9 (22.5%) | 12 (32.4%) |
| Hemoglobin (mmoL/L) | 7.6 ± 0.8 | 7.6 ± 0.7 | 7.7 ± 0.9 |
| Creatinine (μmol/L) | 649 ± 203 | 650 ± 230 | 648 ± 174 |
| Calcium (mmoL/L) | 2.37 ± 0.17 | 2.4 ± 0.19 | 2.4 ± 0.17 |
| Phosphate (mmoL/L) | 1.49 ± 0.31 | 1.5 ± 0.3 | 1.5 ± 0.3 |
| β-blocker | 43 (55.8%) | 22 (55.0%) | 21 (56.8%) |
| ACEI/ARB | 41 (53.2%) | 22 (55.0%) | 19 (51.4%) |
| Statins | 55 (71.4%) | 28 (70.0%) | 27 (72.3%) |
| PWV (m/s) | 10.9 ± 3.3 | 9.6 ± 2.8 | 12.3 ± 3.3* |
*P < 0.05 between patients with E/SRIVR < 236 and patients with E/SRIVR ≥ 236.
ACEI/ARB: angiotensin-converting enzyme inhibitors or receptor blockers; BSA: body surface area; NYHA: New York Heart Association; PWV: pulse wave velocity.